+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Phenotypic and functional lymphocyte recovery after CD34+-enriched versus non-T cell-depleted autologous peripheral blood stem cell transplantation



Phenotypic and functional lymphocyte recovery after CD34+-enriched versus non-T cell-depleted autologous peripheral blood stem cell transplantation



Journal of HematoTherapy and Stem Cell Research 9(5): 727-736



To determine the effect of CD34+ selection on immune recovery after high-dose chemo/radiotherapy in the setting of autologous stem cell transplantation (ASCT), we analyzed quantitative and qualitative lymphocyte reconstitution for up to 1 year post-transplantation in 27 consecutive adult patients receiving either CD34+-enriched or unmanipulated autologous stem cell (SC) grafts. Pretransplant immunological parameters were identical for both treatment groups. Total lymphocyte counts as well as CD3+ T cells provided a similar course of recovery in both cohorts, returning to baseline values within the first 3 months. There were no significant differences in the reconstitution kinetics of CD4+, CD8+, CD45RA+, and CD45RO+ T cells. CD4+ and CD45RA+ T cells between the two groups were significantly decreased within the first 6 months, returning to pretransplant baseline values by 1 year. Although within the first 3 months the majority of CD3+ cells were activated as demonstrated by expression of HLA-DR, we observed a significant loss of CD25+ T cells in both groups within the first 6 months. B cell numbers returned to baseline values within 3 months but in vivo B cell function measured by serum immunoglobulin M (IgM) and IgA levels did not recover as early as 6 months post-transplantation. T cell function measured by proliferation in response to the lectins phytohemagglutinin (PHA) and Concanavalin A (ConA) and to alloantigens in the mixed lymphocyte reaction (MLR) was significantly impaired, but tended to return to pretransplant baseline values by 1 year. Although preliminary, our results provide strong evidence that T cell depletion (TCD) by CD34+ enrichment using the CellPro device does not result in delayed phenotypic immune reconstitution after autologous peripheral blood stem cell transplantation (PB-SCT). Even in the absence of a high thymic T cell regenerative capacity in adults, T cell numbers and subset distributions were restored within the time frame studied. T and B cell function, however, remained significantly impaired for a prolonged period of time (>6 months after SCT) with a more profound defect in patients autografted with CD34+-enriched SC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 046973859

Download citation: RISBibTeXText

PMID: 11091497

DOI: 10.1089/15258160050196777


Related references

Poor lymphocyte recovery following CD34-selected autologous peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. British Journal of Haematology 105(2): 349-360, 1999

CD34+-enriched-CD19+-depleted autologous peripheral blood stem cell transplantation for chronic lymphoproliferative disorders: High purging efficiency but increased risk of severe infections. Experimental Hematology (Charlottesville) 30(7): 824-830, 2002

Donor T lymphocyte engraftment is facilitated by higher CD34 cell doses in T cell depleted myeloablative allogeneic peripheral blood stem cell transplantation. Blood 102(11): 709a, 2003

Frequent viral infections and delayed CD4+ cell recovery following CD34+ cell-selected autologous peripheral blood stem cell transplantation. International Journal of Hematology 70(3): 193-199, 1999

Relationship of CD34+ cell dose to hematopoietic recovery and transfusion requirements following autologous peripheral blood stem cell transplantation. Blood 94(10 Suppl. 1 Part 2): 334b, 1999

Autologous T cell depleted CD34+ peripheral blood stem cell transplantation in four patients with refractory rheumatoid arthritis and juvenile chronic arthritis. Arthritis & Rheumatism 42(9 Suppl. ): S77, 1999

Diminished T-cell recovery after CD34(+) selected autologous peripheral blood stem cell transplantation increases the risk of cytomegalovirus infection. Haematologica 86(6): 667-668, 2001

Phenotypic analysis and characterization of CD34+ cells from normal human bone marrow, cord blood, peripheral blood, and mobilized peripheral blood from patients undergoing autologous stem cell transplantation. Clinical Immunology & Immunopathology. 70(1): 10-18, 1994

Retrospective comparison of CD34-selected allogeneic peripheral blood stem cell transplantation followed by CD8-depleted donor lymphocyte infusions with unmanipulated bone marrow transplantation. Hematology 7(3): 137-143, 2002

Treatment of follicular and mantle cell non-Hodgkins lymphoma with anti-CD20 antibody Rituximab after high-dose chemotherapy with autologous CD34+ enriched peripheral blood stem cell transplantation. Blood 96(11 Part 1): 482a-483a, 2000

Hematological recovery after autologous peripheral blood stem cell transplantation according to CD34+ cells and CFU-GM infused. Blood 94(10 Suppl. 1 Part 2): 360b, 1999

CD34+/CD41a+ cells best predict platelet recovery after autologous peripheral blood stem cell transplantation. Bone: 1217-1222, E 2, 1998

Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin's lymphoma. Bone Marrow Transplantation 34(1): 43-49, 2004

Lymphocyte recovery as a positive predictor of prolonged survival after autologous peripheral blood stem cell transplantation in T-cell non-Hodgkin lymphoma. Blood 102(11): 632a, 2003

Bone marrow versus peripheral blood versus CD34+ progenitors as the source of stem cell for autologous transplantation in multiple myeloma. British Journal of Haematology 102(1): 6, 1998